Alnylam Pharmaceuticals reported Q3 2026 net income of $2.167 billion, up from $292.683 million a year earlier, with a $1.9 billion income tax benefit shaping the comparison. The quarter ended Sept. 30.
Total revenue increased 17% to $1.458 billion. Net product revenue rose 52% to $1.292 billion. Diluted earnings per share were $15.72 under generally accepted accounting principles (GAAP) and $16.26 on a non-GAAP basis.
Alnylam tied product revenue growth chiefly to AMVUTTRA and GIVLAARI: demand for AMVUTTRA increased, and more patients received GIVLAARI. Fewer patients treated with ONPATTRO partly offset those gains. The company reiterated its 2026 guidance.
EconoTimes’ earlier review of Q3 health care earnings found that 22 of 23 companies beat EPS estimates, while 16 reported higher earnings than a year earlier.



